Literature DB >> 15770467

What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

B Ahrén1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15770467     DOI： 10.1007/s00125-005-1706-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  26 in total

1.  Intraperitoneal PACAP administration decreases blood glucose in GK rats, and in normal and high fat diet mice.

Authors:  T Yada; M Sakurada; K Filipsson; M Kikuchi; B Ahrén
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Insulinotropin PACAP potentiates insulin action. Stimulation of glucose uptake in 3T3-LI adipocytes.

Authors:  T Yada; M Nakata; S Shioda
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 3.  The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function.

Authors:  K Filipsson; M Kvist-Reimer; B Ahrén
Journal:  Diabetes       Date:  2001-09       Impact factor: 9.461

4.  Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice.

Authors:  Bo Ahrén
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2004-02       Impact factor: 3.619

5.  The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

Authors:  M A Nauck; A El-Ouaghlidi
Journal:  Diabetologia       Date:  2005-03-11       Impact factor: 10.122

Review 6.  Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Authors:  R Mentlein
Journal:  Regul Pept       Date:  1999-11-30

7.  Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

Authors:  M Kvist Reimer; J J Holst; B Ahrén
Journal:  Eur J Endocrinol       Date:  2002-05       Impact factor: 6.664

8.  Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion.

Authors:  A M Lambeir; C Durinx; P Proost; J Van Damme; S Scharpé; I De Meester
Journal:  FEBS Lett       Date:  2001-11-02       Impact factor: 4.124

9.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

Authors:  Mette Zander; Sten Madsbad; Jan Lysgaard Madsen; Jens Juul Holst
Journal:  Lancet       Date:  2002-03-09       Impact factor: 79.321

Review 10.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

Authors:  Jens Juul Holst; Jesper Gromada
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08       Impact factor: 4.310
View more
  3 in total

Review 1.  How do different GLP-1 mimetics differ in their actions?

Authors:  Simeon Pierre Choukem; Jean-François Gautier
Journal:  Curr Diab Rep       Date:  2006-11       Impact factor: 4.810

2.  New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.

Authors:  Baptist Gallwitz
Journal:  Rev Diabet Stud       Date:  2005-08-10

Review 3.  Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.

Authors:  Baptist Gallwitz
Journal:  Vasc Health Risk Manag       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.